Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma

NCT03719898 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Slow accrual

Conditions

Anaplastic Large Cell Lymphoma, ALK-Positive

Interventions

DRUG: Brigatinib

Sponsor

Fox Chase Cancer Center